Beachbody (NASDAQ:BODI) executives used the company’s fourth quarter 2025 earnings call to emphasize that 2025 marked a transition year following the exit from its former multi-level marketing (MLM) ...

USANA Health Sciences is executing a strategic pivot from its declining MLM core to high-growth brands Hiya and Rise Wellness ...

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the building materials stocks, including Martin ...

Construction materials supplier Martin Marietta Materials (NYSE:MLM) missed Wall Street’s revenue expectations in Q4 CY2025, ...

Primary endpoint met with statistically significant improvement (mean change of +2.13; p<0.001) on the Microcystic Lymphatic ...

New infrastructure strengthens Africa-based clinical trial logistics, reducing costs and accelerating timelines for ...

District reports below-normal aquifer readings in two of three regions through late February.

Phase 3 SELVA trial data show QTORIN rapamycin gel significantly improves microcystic lymphatic malformation severity in adults and children.

McFarlane Lake Mining (CSE: MLM; US-OTC: MLMLF) reported additional results from its drilling exploration campaign at its ...

Investing.com - Stephens lowered its price target on Martin Marietta Materials (NYSE:MLM) to $735.00 from $740.00 on Friday, while maintaining an Overweight rating on the construction materials ...

Third-party software supplier breached leading to leak of doctors' notes Around 15.8 million administrative files were stolen ...

Palvella Therapeutics (PVLA) stock jumps as a Phase 3 trial for the company's lead asset, Qtorin rapamycin, hits key endpoints against a rare skin disorder. Read more here.